Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study

被引:6
作者
Zhang, Qiongwen [1 ,2 ]
He, Ping [3 ]
Tian, Tinglun [3 ]
Yan, Xi [3 ]
Huang, Juan [4 ]
Zhang, Zhang [5 ]
Zheng, Hong [3 ,6 ]
Zhong, Xiaorong [3 ,6 ]
Luo, Ting [3 ,6 ]
机构
[1] Sichuan Univ, Canc Ctr, West China Hosp, Dept Radiat Oncol,Dept Head & Neck Oncol, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Breast Dis Ctr, Canc Ctr, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Innovat Ctr Biotherapy, Multi Lab Breast Dis,State Key Lab Biotherapy,Natl, Chengdu, Peoples R China
关键词
HER2-positive breast cancer; real-world studies; brain metastase; pyrotinib; tyrosine kinase inhibitors; TYROSINE KINASE INHIBITOR; BRAIN METASTASES; CHEMOTHERAPY; TRASTUZUMAB; CISPLATIN;
D O I
10.3389/fphar.2023.1100556
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Pyrotinib, a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor, shows encouraging anticancer activity and acceptable tolerability in multiple phase II and phase III randomized clinical trials, but the real-world data of pyrotinib, especially the outcomes in HER2-positive metastatic breast cancer, have been rarely reported. Here, we evaluated the treatment outcomes of pyrotinib in real-world practice in patients with HER2-positive metastatic breast cancer (MBC).Methods: This was a prospective, real-world, observational cohort study. Through the Breast Cancer Information Management System, HER-2 positive MBC patients treated with pyrotinib between 2017/06 and 2020/09 were included. Provider-reported objective response rate, progression-free survival (PFS), and overall survival (OS) were considered in the assessment of treatment outcomes. Tumor responses to pyrotinib treatment were calculated using RECIST 1.1. Adverse events were evaluated using clinical records.Results: The trial involved 113 individuals who were receiving pyrotinib treatment, with an average age of 51 years. Complete response, partial response and stable disease were observed in 9 (8.0%), 66 (58.4%), and 17 (15.0%) patients, respectively, while progressive disease was recorded in 20 (17.7%) patients. After a median follow-up of 17.2 months, the median PFS was 14.1. The most common adverse events of any grade were diarrhea (87.6%), vomiting (31.9%), and palmar-plantar erythrodysesthesia (26.6%). Among the patients with brain metastases, the median PFS and OS were 15.2 and 19.8 months, respectively. In addition, pyrotinib has similar efficacy in various subtypes of HER2-positive MBC patients, as shown by the lack of a significant difference of PFS and OS among pyrotinib-treated patients with or without brain metastases, or patients using pyrotinib as first-line, second-line, third-line or beyond therapies.Conclusion: Our real-world results demonstrated equivalent clinical efficacy in HER-2 positive MBC patients compared to phase II and phase III clinical trials with pyrotinib, and promising outcomes in patients with brain metastases.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
    Piezzo, Michela
    D'Aniello, Roberta
    Avallone, Ilaria
    Barba, Bruno
    Cianniello, Daniela
    Cocco, Stefania
    D'Avino, Antonio
    Di Gioia, Germira
    Di Lauro, Vincenzo
    Fusco, Giuseppina
    Piscitelli, Raffaele
    von Arx, Claudia
    De Laurentiis, Michelino
    Maiolino, Piera
    PHARMACEUTICS, 2021, 13 (05)
  • [42] Real-world outcomes among patients with HER2+metastatic breast cancer with brain metastases
    DeBusk, Kendra
    Ike, Chiemeka
    Lindegger, Nicolas
    Schwartz, Naomi
    Surinach, Andy
    Liu, Yutong
    Forero-Torres, Andres
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (06) : 657 - 666
  • [43] Efficacy and safety of pyrotinib in the treatment of HER2-positive liver metastatic advanced breast cancer
    Li, Yongxia
    Li, Yong
    Li, Taolang
    He, Mingyuan
    Chang, Jianying
    Cao, Hui
    Luo, Daiqin
    Lv, Junyuan
    Zou, Yunbi
    Zheng, Yuyan
    Ran, Li
    Yang, Feiyue
    Huang, Li
    Cheng, Xiaoming
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [44] Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)
    Gonzalez-Santiago, Santiago
    Saura, Cristina
    Ciruelos, Eva
    Luis Alonso, Jose
    de la Morena, Pilar
    Santisteban Eslava, Marta
    Gallegos Sancho, Maria Isabel
    de Luna, Alicia
    Dalmau, Elsa
    Servitja, Sonia
    Ruiz Borrego, Manuel
    Ignacio Chacon, Jose
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (02) : 469 - 479
  • [45] Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
    Lee, Yong-Pyo
    Lee, Min-Sang
    Kim, HongSik
    Kim, Ji-Yeon
    Ahn, Jin Seok
    Im, Young-Hyuck
    Park, Yeon Hee
    CANCER RESEARCH AND TREATMENT, 2022, 54 (04): : 1130 - 1137
  • [46] Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population
    Gagliato, Debora
    Reinert, Tomas
    Rocha, Claudio
    Tavares, Monique
    Pimentel, Samio
    Fuzita, William
    Araujo, Marcia
    Matias, Danielli
    Aleixo, Sabina
    Franca, Bruno
    Magaton, Erida
    Brito, Natalia
    Cardoso, Ana Carolina
    Castilho, Vivienne
    ONCOLOGY AND THERAPY, 2024, 12 (03) : 437 - 449
  • [47] The efficacy and safety of pyrotinib in treating HER2-positive breast cancer patients with brain metastasis: A multicenter study
    Gao, Min
    Fu, Chao
    Li, Shanshan
    Chen, Fang
    Yang, Yongteng
    Wang, Chunjian
    Qin, Jie
    Liu, Shuaishuai
    Zhang, Ranran
    Wang, Changyuan
    Zong, Jinbao
    Meng, Liping
    Meng, Xiangjiao
    CANCER MEDICINE, 2022, 11 (03): : 735 - 742
  • [48] A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
    Vici, Patrizia
    Pizzuti, Laura
    Michelotti, Andrea
    Sperduti, Isabella
    Natoli, Clara
    Mentuccia, Lucia
    Di Lauro, Luigi
    Sergi, Domenico
    Marchetti, Paolo
    Santini, Daniele
    Magnolfi, Emanuela
    Iezzi, Laura
    Moscetti, Luca
    Fabbri, Agnese
    Cassano, Alessandra
    Grassadonia, Antonino
    Omarini, Claudia
    Piacentini, Federico
    Botticelli, Andrea
    Bertolini, Ilaria
    Scinto, Angelo Fedele
    Zampa, Germano
    Mauri, Maria
    D'Onofrio, Loretta
    Sini, Valentina
    Barba, Maddalena
    Maugeri-Sacca, Marcello
    Rossi, Ernesto
    Landucci, Elisabetta
    Tomao, Silverio
    Alberti, Antonio Maria
    Giotta, Francesco
    Ficorella, Corrado
    Adamo, Vincenzo
    Russo, Antonio
    Lorusso, Vito
    Cannita, Katia
    Barni, Sandro
    Laudadio, Lucio
    Greco, Filippo
    Garrone, Ornella
    Della Giulia, Marina
    Marolla, Paolo
    Sanguineti, Giuseppe
    Di Cocco, Barbara
    Ciliberto, Gennaro
    De Maria, Ruggero
    Gamucci, Teresa
    ONCOTARGET, 2017, 8 (34) : 56921 - 56931
  • [49] A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study
    Elisabet Lidbrink
    E. Chmielowska
    B. Otremba
    A. Bouhlel
    S. Lauer
    M. Liste Hermoso
    E. Nüesch
    M. Shing
    V. Misra
    Breast Cancer Research and Treatment, 2019, 174 : 187 - 196
  • [50] Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study
    Fangchao Zheng
    Feng Du
    Zixuan Yang
    Xue Wang
    Jian Yue
    Yun Ling
    Peng Yuan
    Discover Oncology, 16 (1)